<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1407245565
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RIAPHYLLIN 60MG/5ML SYRUP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        THEOPHYLLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Syrup
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of the medicine is Riaphyllin Syrup. It is used to treat asthma and other conditions where</p><p>breathing is difficult. It also helps to prevent asthma attacks. The active ingredient in Riaphyllin Syrup is theophylline, which causes the muscle lining of the airways to relax.</p><p>Your doctor or pharmacist may recommend Riaphyllin Syrup for another purpose.</p><p>If you are not sure why the patient is taking this medicine, please ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>RIAPHYLLIN Syrup should not be taken if the patient is allergic to:</strong></p><ul><li>&nbsp;Theophylline</li><li>Aminophylline</li><li>Caffeine</li><li>Any of the ingredients listed in section 6.</li></ul><p><strong>Some of the symptoms of an allergic reaction may include:</strong></p><ul><li>&nbsp;shortness of breath</li><li>&nbsp;wheezing or difficulty breathing</li><li>swelling of the face, lips, tongue or other parts of the body</li><li>rash, itching or hives on the skin</li></ul><p>Do not give this medicine to a child under the age of 2 years unless a doctor has recommended the medicine.</p><p>Do not take this medicine or give it to a child after the expiry date printed on the pack or if the packaging shows signs of tampering.</p><p>If it has expired or is damaged, return it to your pharmacist for disposal.</p><p><strong>If you are not sure whether the patient should start taking this medicine, talk to your doctor</strong></p><p><strong>or pharmacist.</strong></p><p>Riaphyllin &nbsp;Syrup has been recommended for the patient only.</p><p><strong>Do not give it to anyone else even if they suffer from the same condition.</strong></p><p><strong>Before starting to take&nbsp;it</strong></p><p>&nbsp;</p><p><strong>Tell your doctor if the patient has allergies to any other medicines, foods, preservatives or</strong></p><p><strong>dyes.</strong></p><p><strong>Tell your doctor or pharmacist if the patient has or has had any of the following medical</strong></p><p><strong>conditions:</strong></p><ul><li>&nbsp;a stomach ulcer or reflux</li><li>an irregular or rapid heartbeat</li><li>any other heart disease</li><li>&nbsp;high blood pressure</li><li>any viral infections or lung infections</li><li>any liver disease</li><li>&nbsp;thyroid disease</li><li>lung disease</li></ul><p><strong>Or else if the patient:</strong></p><ul><li>has a fever</li><li>is pregnant or breastfeeding</li><li>is taking any other medicines for asthma</li></ul><p>&nbsp;</p><p><strong>If you have not told your pharmacist or doctor about any of the above, tell him/her before the patient starts taking the medicine.</strong></p><p><em>&nbsp;</em></p><p><strong>Taking other medicines</strong></p><p>Tell your doctor or pharmacist if the patient is taking any other medicines, including any that</p><p>you get without a prescription from your pharmacy or health food shop.</p><p>Some medicines and Riaphyllin Syrup may interfere with each other. These include:</p><ul><li>antibiotics such as erythromycin (Eryc and others), clarithromycin (Klacid), ciprofloxacin (Ciproxin)</li><li>enoxacin (Enoxin), rifampicin (Rifadin and others) or isoniazid</li><li>medicines used to treat ulcers such as cimetidine (Tagamet and others), ranitidine (Zantac and others)</li><li>allopurinol (Zyloprim and others)</li><li>propranolol (Inderal and others)</li><li>frusemide (Lasix and others)</li><li>medicines used to help lower high blood pressure such as verapamil (Isoptin and others), diltiazem (Cardizem and others), nifedipine (Adalat and others)</li><li>mexiletine (Mexitil)</li><li>medicines used to treat epilepsy or fits such as phenytoin (Dilantin), phenobarbitone or carbamazepine (Tegretol and others)</li><li>tacrine (Cognex)</li><li>lithium</li><li>thiabendazole (Mintezol)</li><li>disulfiram (Antabuse)</li><li>oral contraceptives (the Pill)</li><li>corticosteroids</li><li>flu vaccine</li><li>interferon</li><li>any remedies that you buy without a prescription, especially cold and flu medicines and products containing &nbsp;St John&#39;s Wort (<em>Hypericum perforatum</em>)</li></ul><p>&nbsp;</p><p>These medicines may be affected by Riaphyllin Syrup or may affect how well it works. The patient may need different amounts of these medicines, or may need to take different medicines.</p><p><strong>Also tell your doctor or pharmacist if the patient drinks any alcohol or smokes cigarettes</strong></p><p><strong>or marijuana.</strong></p><p>Your doctor or pharmacist may have more information on medicines to be careful with or to</p><p>avoid while taking this medicine.</p><p><strong>Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.</strong></p><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding</strong></p><p>Your doctor or pharmacist can discuss with you the risks and benefits involved.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines </strong></p><p>Riaphyllin Syrup have no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure</strong>.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The dose for adults is usually 25mL every six hours. However, this dose may be increased or decreased by your doctor.</p><p>For children over 2 years old, the dose of Riaphyllin Syrup depends on the weight of the child</p><p>(1mL/kg of bodyweight up to a maximum of 25mL every six hours).</p><ul><li>Children 2-4 years, 12-16 kg: 10-15mL every 6 hours</li><li>Children 4-6 years, 16-20 kg: 15-20mL every 6 hours</li><li>Children 6-12 years, 20-41 kg: 20-25mL every 6 hours</li><li>Adults and children over 12 years: 25mL every 6 hours</li></ul><p>Riyaphyllin Syrup is not suitable for children younger than 2 years of age except on the advice of a</p><p>doctor.</p><p><strong>How to take it</strong></p><p>It is best to take Riaphyllin Syrup one hour before food with a glass of water. However if it upsets</p><p>the patient&#39;s stomach it should be taken with or immediately after food.</p><p><em>&nbsp;</em></p><p><strong>While the patient is taking Riaphyllin Syrup</strong></p><p>Riaphyllin Syrup works best when there is a certain amount of theophylline, the active ingredient, in</p><p>the blood. Your doctor may sometimes need to take samples of blood to check the level of theophylline.</p><p>&nbsp;</p><p><strong>If you take more RIAPHYLLIN &nbsp;than you should</strong></p><p>If you think that you or anyone else may have taken too much Riaphyllin Syrup contact your doctor or go to Accident and Emergency at your nearest hospital IMMEDIATELY. Do this even if there are no signs of discomfort or poisoning.</p><p>If you or your child has taken too much Riaphyllin Syrup you may feel sick and vomit. You may feel</p><p>irritable, agitated or anxious. You may be unable to sleep.</p><p>In severe cases, your heart may beat faster and irregularly and you may have a high body temperature, be very thirsty, be very confused and have fits.</p><p>&nbsp;</p><p><strong>If you forget to take RIAPHYLLIN </strong></p><p>If the patient forgets to take Riaphyllin Syrup, take it as soon as you remember. However, if it is more than 4 hours late, skip the dose that the patient missed. Take the next dose at the normal time.</p><p>Never take a double dose to make up for a missed dose.</p><p>If the patient has trouble remembering when to take the medicine, ask your pharmacist for some hints.</p><p>&nbsp;</p><p><strong>While you are using Riaphyllin Syrup</strong></p><p><strong>Things you must do</strong></p><p>If the patient is about to be started on any new medicine remind your doctor and pharmacist</p><p>that the patient is taking Riaphyllin Syrup.</p><p>Tell any other doctors, dentists and pharmacists who treat the patient that the patient is taking this medicine.</p><p>If the patient is going to have surgery, tell the surgeon or anaesthetist that the patient is taking this&nbsp;</p><p>medicine.</p><p>It may affect other medicines used during surgery.</p><p>If the patient becomes pregnant while taking this medicine, tell your doctor immediately.</p><p><strong>&nbsp;</strong></p><p><strong>Things you must not do</strong></p><p>The patient must not take Riaphyllin Syrup to treat any other complaints unless the doctor or pharmacists tells them to.</p><p>Do not give this medicine to anyone else, even if they have the same condition as the patient.</p><p>The patient should not stop taking the medicine or lower the dosage without checking with the pharmacist or doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Things to be careful of</strong></p><p>Be careful when drinking alcohol or smoking cigarettes or marijuana, these can interfere with how well Riaphyllin Syrup works.</p><p>&nbsp;</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Riaphyllin Syrup &nbsp;can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you notice any of the following that worry you:</strong></p><ul><li>nausea, vomiting, stomach pain, loss of appetite</li><li>heartburn&nbsp;</li><li>headache</li><li>difficulty sleeping</li><li>feeling restless, nervous or irritable</li></ul><p><strong>Tell your doctor or pharmacist as soon as possible if you notice any of the following:</strong></p><ul><li>diarrhoea</li><li>&nbsp;abnormal heartbeat</li><li>low blood pressure</li><li>&nbsp;flushing, skin rash</li><li>&nbsp;rapid breathing</li><li>&nbsp;increased or decreased urine flow</li><li>&nbsp;blood in the urine</li><li>high blood glucose</li><li>&nbsp;hair loss</li><li>&nbsp; worsening of a stomach ulcer</li><li>&nbsp;fast or irregular heartbeat</li><li>tremor</li></ul><p>The above list includes serious side effects that may require medical attention. Serious side</p><p>effects are rare.</p><p><strong>If any of the following happens, tell your doctor immediately or go to Accident and Emergency at your nearest hospital:</strong></p><ul><li>&nbsp; very irregular or faster heartbeat</li><li>&nbsp;fits</li><li>blood in the vomit</li></ul><p>The above list includes very serious side effects. You may need urgent medical attention or</p><p>hospitalisation. These side effects are very rare.</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you notice anything that is making the patient feel unwell.</strong></p><p>Other side effects not listed above may also occur in some people.</p><p>&nbsp;</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, Please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once the pack has been opened the contents should be used within 28 days.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep in the original pack tightly closed to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use RIAPHYLLIN &nbsp;after the expiry date which is stated on the carton .The Expiry date refers to the last day of that month</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each 5 ml contains Theophylline (BP) 60 mg</p><p>Excipients:</p><p>Sucrose, Sorbitol Solution 70% N.C, Glycerol, Propylene Glycol, Sodium Hydroxide ,Sodium Sulphite Anhydrous ,Saccharin Sodium ,Fruit Cocktail Flavor ID-21244 ,Peppermint Flavor C-7531 ,Purified water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                RIAPHYLLIN  is a Clear, colourless to pale yellow syrup with characteristic fruity and peppermint odour free from foreign particles.
Pack: 100ml  Amber coloured glass bottle with white child resistant plastic cap


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O.Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing Authorisation holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in (06/2017)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم الدواء هو ريافللين شراب. يتم استخدامه لعلاج الربو وغيرها من الحالات مثل صعوبة التنفس. كما أنه يساعد على منع نوبات الربو. المادة الفعالة في شراب ريافللين هي الثيوفللين، التي تسبب استرخاء العضلات التي تبطن المجاري الهوائية.</p><p dir="RTL">قد يوصي طبيبك أو الصيدلي بتناول شراب ريافللين لغرض آخر.</p><p dir="RTL">إذا لم تكن متأكدا من سبب تناول المريض لهذا الدواء، يرجى استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا ينبغي تناول شراب ريافللين إذا كان المريض يعاني حساسية من</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثيوفللين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمينوفللين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكافيين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي من المكونات المدرجة في القسم 6</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض أعراض رد الفعل التحسسي قد تشمل</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز أو صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والشفتين واللسان أو أجزاء أخرى من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي وحكة أو بثور على الجلد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينبغي إعطاء هذا الدواء لطفل دون سن الثانية ما لم ينصح الطبيب بهذا الدواء.</p><p dir="RTL">لا تتناول هذا الدواء أو تقوم بإعطائه لطفل بعد تاريخ انتهاء الصلاحية المطبوع على العبوة أو إذا كانت العبوة تظهر علامات العبث عليها .</p><p dir="RTL">إذا انتهت فترة الصلاحية أو تلفت، قم بإعادتها إلى الصيدلي للتخلص منها.</p><p dir="RTL"><strong>إذا لم تكن متأكدا مما إذا كان المريض يجب أن يبدأ في تناول هذا الدواء، تحدث مع طبيبك أو الصيدلي.</strong></p><p dir="RTL">شراب ريافللين ينصح بتناوله للمرضى فقط<strong> .</strong></p><p dir="RTL"><strong>لا تعطيه لأي شخص آخر حتى لو كانوا يعانون من نفس الحالة.</strong></p><p dir="RTL">قبل البدء في تناول الدواء</p><p dir="RTL">أخبر طبيبك إذا كان المريض لديه حساسية من أي أدوية أخرى، أطعمة، مواد حافظة أو الأصباغ .</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كان المريض لديه أو كان لديه أي من الحالات الطبية التالية:</p><ul dir="rtl"><li>قرحة في المعدة أو ارتجاع</li><li>عدم انتظام ضربات القلب</li><li>&nbsp;أي من أمراض القلب الأخرى</li><li>ضغط دم مرتفع</li><li>أي عدوى فيروسية أو التهابات في الرئة</li><li>أي من أمراض الكبد</li><li>مرض الغدة الدرقية</li><li>أمراض الرئة</li><li>أو إذا كان المريض:</li><li>لديه حمى</li><li>حامل أو مرضعة</li><li>تناول أي أدوية أخرى للربو</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا لم تخبر الصيدلي أو الطبيب عن أي مما سبق، أخبره بذلك قبل أن يبدأ المريض في تناول الدواء.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى</strong><strong> </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كان المريض يتناول أي أدوية أخرى، بما في ذلك الأدوية التي تحصل عليها بدون وصفة طبية من الصيدلية أو متجر المواد الغذائية الصحية.</p><p dir="RTL">بعض الأدوية و شراب ريافللين قد تتداخل مع بعضها. وتشمل هذه:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية مثل الاريثروميسين (إيريك وغيرها)، كلاريثروميسين (كلاسيد)، سيبروفلوكساسين (سيبروكسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إينوكساسين (إينوكسين)، ريفامبيسين (ريفادين وغيرها) أو أيزونيازيد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج القرحة مثل سيميتيدين (تاجامت وغيرها)، رانيتيدين (زانتاك وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألوبيورينول (زيلوبريم وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبرانولول (إندرال وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فروسيميد (لاسيكس وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للمساعدة في خفض ضغط الدم المرتفع مثل فيراباميل (إيسوبتين وآخرون)، ديلتيازيم (كارديزم وآخرون)، نيفيديبين (أدالات وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميكسيليتين (مكسيتيل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الصرع أو النوبات مثل الفينيتوين (ديلانتين)، الفينوباربيتون أو كاربامازيبين (تيجريتول وغيرها)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكرين (كوغنيكس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيابندازول (مينتيزول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديسولفيرام (أنتابيوس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل عن طريق الفم (حبوب منع الحمل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات القشرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لقاح الانفلونرا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانترفيرون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي علاجات تشتريها بدون وصفة طبية، خاصة أدوية علاج البرد والمنتجات التي تحتوي على نبتة سانت جون(هيبيريكوم بيرفوراتوم )</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تتأثر هذه الأدوية من شراب ريافللين أو قد تؤثر على مدى فاعليته<strong>. </strong></p><p dir="RTL">قد يحتاج المريض إلى كميات مختلفة من هذه الأدوية، أو قد يحتاج إلى تناول أدوية مختلفة.</p><p dir="RTL"><strong>أخبر أيضا طبيبك أو الصيدلي إذا كان المريض يشرب أي كحول أو يدخن السجائر أو الماريجوانا</strong><strong>.</strong></p><p dir="RTL">قد یکون لدى الطبيب أو الصيدلي المزيد من المعلومات حول الأدوية الواجب توخي الحذر معها أو تجنب&nbsp; تناولها أثناء تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يرجى إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، حتى تلك التي لم توصف لك</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يمكن لطبيبك أو الصيدلي أن يناقش معك المخاطر والمنافع ذات الصلة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">شراب ريافللين ليس له تأثير يذكر على القدرة على قيادة واستخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما قال لك الطبيب أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">الجرعة للبالغين عادة 25 مل كل ست ساعات. ومع ذلك، قد يتم زيادة أو خفض هذه الجرعة من قبل الطبيب.</p><p dir="RTL">بالنسبة للأطفال الذين تزيد أعمارهم عن سنتين، تعتمد جرعة شراب ريافللين على وزن الطفل (1 مل / كجم من وزن الجسم تصل إلى 25 مل كحد أقصى كل ست ساعات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال 2- 4 سنوات ، 12-16 كجم: 10-15 مل كل 6 ساعات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال 4- 6 سنوات ، 16-20 كجم: 15-20 مل كل 6 ساعات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال 6-12 سنوات ، 20-41 كجم:20-25 مل كل 6 ساعات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين والأطفال فوق 12 سنة: 25 مل كل 6 ساعات</p><p dir="RTL">شراب ريافللين ليس مناسب للأطفال الذين تقل أعمارهم عن 2 سنة من العمر إلا بناء على نصيحة من الطبيب.</p><p dir="RTL"><strong>كيفية التناول</strong><strong> </strong></p><p dir="RTL">من الأفضل أن تتناول شراب ريافللين ساعة واحدة قبل الطعام مع كوب من الماء. ومع ذلك إذا كان يزعج معدة المريض يجب أن تؤخذ&nbsp; مع أو بعد الطعام مباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء تناول المريض شراب ريافللين </strong></p><p dir="RTL">شراب ريافللين يعمل بشكل أفضل عندما يكون هناك كمية معينة من الثيوفللين، المادة الفعالة، في الدم. قد يحتاج طبيبك أحيانا إلى أخذ عينات من الدم للتحقق من مستوى الثيوفللين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت ريافللين أكثرمما يجب</strong></p><p dir="RTL">إذا كنت تعتقد أنك أو أي شخص آخر قد تناولت الكثير من شراب ريافللين اتصل بطبيبك أو اذهب إلى قسم الحوادث والطوارئ في أقرب مستشفى على الفور. قم بذلك حتى إذا لم تكن هناك أي علامات تدل على عدم الارتياح أو التسمم. إذا كنت أنت أو طفلك قد تناولت الكثير من شراب ريافللين قد تشعر بالمرض والقيء. قد تشعر بالانزعاج، الاهتياج أو القلق. قد لا تتمكن من النوم.</p><p dir="RTL">في الحالات الشديدة، ضربات قلبك ستكون أسرع وغير منتظمة وقد ترتفع درجة حرارة الجسم ، تشعر بالعطش الشديد، تشعر بالارتباك ونوبات .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول ريافللين</strong></p><p dir="RTL">إذا نسي المريض أن يتناول شراب ريافللين ، تناول الجرعة بمجرد أن تتذكر. ومع ذلك، إذا تأخرت أكثر من 4 ساعات ، تخطي الجرعة المنسية. تناول الجرعة التالية في الوقت المعتاد.</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا كان المريض لديه صعوبة في تذكر متى يتناول الدواء، اطلب من الصيدلي الحصول على بعض المساعدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء تناول شراب ريافللين </strong></p><p dir="RTL"><strong>الأشياء التي يجب القيام بها</strong></p><p dir="RTL">إذا كان المريض على وشك أن يستخدم أي دواء جديد يجب تذكير الطبيب والصيدلي أن المريض يتناول شراب ريافللين.</p><p dir="RTL">يجب اخبار أي طبيب، طبيب أسنان أو صيدلي الذين يعالجون المريض بأنه يتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان المريض سوف يخضع لعملية جراحية، أخبر الجراح أو طبيب التخدير أن المريض يتناول هذا الدواء.</p><p dir="RTL">قد تؤثر على الأدوية الأخرى المستخدمة أثناء الجراحة.</p><p dir="RTL">إذا كانت المريضة حاملا أثناء تناول هذا الدواء، أخبر طبيبك فورا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات</strong></p><p dir="RTL">كن حذرا عند شرب الكحول أو تدخين السجائر أو الماريجوانا، هذه يمكن أن تتداخل مع كيفية عمل شراب ريافللين.</p><p dir="RTL"><strong>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب ريافللين &nbsp;آثارا جانبية على الرغم من أنه ليس كل شخص تحدث له الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا لاحظت أي مما يلي قد يقلقك</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، والتقيؤ، وآلام في المعدة، وفقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الارتياح، العصبية أو الإهتياج</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي في أقرب وقت ممكن إذا لاحظت أي مما يلي</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم منخفض</p><p dir="RTL">احمرار، طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنفس سريع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو انخفاض تدفق البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة الجلوكوز في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم قرحة المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعشه</p><p dir="RTL">تتضمن القائمة المذكورة أعلاه آثارا جانبية خطيرة قد تتطلب عناية طبية. الأثار الجانبية الخطيرة نادرة.</p><p dir="RTL"><strong>إذا حدث أي مما يلي، أخبر طبيبك فورا أو انتقل إلى قسم الحوادث والطوارئ في أقرب مستشفى:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب غير منتظمة جدا أو أسرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في القيء</p><p dir="RTL">وتشمل القائمة أعلاه آثار جانبية خطيرة جدا. قد تحتاج إلى عناية طبية عاجلة أو العلاج في المستشفيات. هذه الآثار الجانبية نادرة جدا.</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا لاحظت أي شيء يجعل المريض يشعر بالتوعك</strong><strong>.</strong></p><p dir="RTL">الآثار الجانبية الأخرى غير المذكورة أعلاه قد تحدث أيضا في بعض الناس.</p><p dir="RTL"><strong>إذا كان أي من الآثار الجانبية خطير، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول أيدي ونظر الأطفال .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; بمجرد فتح العبوة، يجب استعمال المستحضر خلال 28 يوماً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية للحماية من الضوء. يغلق بإحكام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لا يستخدم بعد تاريخ نهاية الصلاحية المدون على العبوة والكرتون . يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كل 5 مل يحتوي على ثيوفللين (دستور الأدوية البريطاني) 60 ملجم</p><p dir="RTL">سواغ:</p><p dir="RTL">السكروز، محلول سوربيتول 70٪ N.C، الجلسرين، البروبيلين جليكول، هيدروكسيد الصوديوم، كبريتات الصوديوم اللامائية، سكارين الصوديوم، نكهة الفواكه المشكلةID-21244 ، نكهة النعناع C-7531، والمياه النقية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سائل شفاف، عديم اللون الى أصفر شاحب له رائحة الفاكهة والنعناع المميزة خالي من الشوائب.</p><p dir="RTL"><strong>حجم العبوة</strong></p><p dir="RTL">عبوة100 مل زجاجية بنية اللون بغطاء بلاستيكي أبيض مقاوم للفتح بواسطة الأطفال .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ (06/2017) 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Riaphyllin SYRUP 100ml  60mg/ 5ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredients:
Each 5 ml contains:
60 mg Theophylline (BP) 
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Syrup Clear, to colourless pale yellow syrup with characteristic fruity and peppermint odour free from foreign particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Riaphyllin is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>DOSAGE AND ADMINISTRATION</strong></p><p><strong>General Considerations </strong>:</p><p>The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400- 1600 mg/day in adults &lt;60 years old and 10-36 mg/kg/day in children 1-9 years old). For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients.</p><p>Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients. For example, at a dose of 900 mg/d in adults &lt;60 years or 22 mg/kg/d in children 1-9 years, the steady state peak serum theophylline concentration will be &lt;10 mcg/mL in about 30% of patients, 10-20 mcg/mL in about 50% and 20-30 mcg/mL in about 20% of patients. The dos e of theophylline must be individualized on the bas is of peak serum theophylline concentration measurements in order to achieve a dos e that will provide maximum potential benefit with minimal risk to adverse effects .</p><p>Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments (See Table V). Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum theophylline concentrations to reach the new steady state. Dosage adjustment should be guided by serum theophylline concentration measurement (see PRECAUTIONS, Laboratory Tests and DOSAGE AND ADMINISTRATION, Table VI). Health care providers should instruct patients and care givers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage (see WARNINGS).</p><p>If the patient&#39;s symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements (see WARNINGS and PRECAUTIONS), serum theophylline concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum theophylline concentrations should be monitored at frequent intervals, e.g., every 24 hours.</p><p>Theophylline distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.</p><p>Table V contains theophylline dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for theophylline dosage adjustment based upon serum theophylline concentrations. Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dos age adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum theophylline concentration.</p><p>Table V. Dosing initiation and titration (as anhydrous theophylline).*</p><p>Infants &lt;1 year old.</p><p>Initial Dos age.</p><p>Premature Neonates :</p><p>&lt; 24 days postnatal age; 1.0 mg/kg every 12 hr</p><p>&ge; 24 days postnatal age; 1.5 mg/kg every 12 hr</p><p>Full term infants and infants up to 52 weeks of age:</p><p><em>Total daily dose (mg) = [(0.2 x age in weeks)+5.0] x (Kg body Wt).</em></p><p>&lt; 26 weeks ; divide dos e into 3 equal amounts administered at 8 hour intervals .</p><p>&ge; 26 weeks of age; divide dos e into 4 equal amounts administered at 6 hour intervals .</p><p>&nbsp;</p><p>Final Dosage.</p><p>Adjusted to maintain a peak steady state serum theophylline concentration of 5-10 mcg/ml in neonates and 10-15 mcg/mL in older infants (see Table VI). Since the time required to reach steady-state is a function of theophylline half-life, up to 5 days may be required to achieve steady state in a premature neonate while only 2-3 days may be</p><p>required in a 6 month old infant without other risk factors for impaired clearance in the absence of a loading dos e. If a serum theophylline concentration is obtained before steady state is achieved, the maintenance dose should not be increased, even if the serum theophylline concentration is &lt;10 mcg/mL.</p><p>&nbsp;</p><p><strong>Children (1-15 years ) and adults (16-60 years ) without risk factors for impaired clearance.</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Titration Step</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Children &lt; 45 kg</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Children &gt; 45 kg and adults</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>1. Starting Dosage</p></td><td style="vertical-align:top"><p>1. 12-14 mg/kg/day up to a maximum of 300 mg/day divided Q4-6 hrs*</p></td><td style="vertical-align:top"><p>1. 300 mg/day divided Q6-8 hrs*</p></td></tr><tr><td style="vertical-align:top"><p>1. After 3 days, if tolerated,</p><p>increase dose to:</p></td><td style="vertical-align:top"><p>1. 16 mg/kg/day up to a maximum</p><p>of 400 mg/day divided Q4-6 hrs*</p></td><td style="vertical-align:top"><p>1. 400 mg/day divided Q6-8 hrs*</p></td></tr><tr><td style="vertical-align:top"><p>1. After 3 more days, if</p><p>tolerated, increase dose to:</p></td><td style="vertical-align:top"><p>1. 20 mg/kg/day up to a maximum</p><p>of 600 mg/day divided Q4-6 hrs*</p></td><td style="vertical-align:top"><p>1. 600 mg/day divided Q6-8 hrs*</p></td></tr></tbody></table><p>&nbsp;</p><p>1. <strong>Patients With Risk Factors For Impaired Clearance, The Elderly (&gt;60 Years ), And Those In Whom It Is Not Feasible To Monitor Serum Theophylline Concentrations :</strong></p><p>1. In children 1-15 years of age, the final theophylline dose should not exceed 16 mg/kg/day up to a maximum of 400 mg/day in the presence of risk factors for reduced theophylline clearance (see WARNINGS) or if it is not feasible to monitor serum theophylline concentrations.</p><p>1. In adolescents &ge;16 years and adults, including the elderly, the final theophylline dose should not exceed 400 mg/day in the presence of risk factors for reduced theophylline clearance (see WARNINGS) or if it is not feasible to monitor serum theophylline concentrations.</p><p>&nbsp;</p><p>1. <strong>Loading Dose for Acute Bronchodilatation:</strong></p><p>1. An inhaled beta-2 selective agonist, alone or in combination with a systemically administered corticosteroid, is the most effective treatment for acute exacerbations of reversible airways obstruction. Theophylline is a relatively weak bronchodilator, is less effective than an inhaled beta-2 selective agonist and provides no added benefit in the treatment of acute bronchospasm.</p><p>If an inhaled or parenteral beta agonist is not available, a loading dose of an oral immediate release theophylline can be used as a temporary measure. A single 5 mg/kg dose of theophylline, in a patient who has not received any theophylline in the previous 24 hours, will produce an average peak serum theophylline concentration of 10 mcg/mL (range 5-15 mcg/mL). If dosing with theophylline is to be continued beyond the loading dose, the</p><p>guidelines in Sections A.1.b., B.3, or C., above, should be utilized and serum theophylline concentration monitored at 24 hour intervals to adjust final dosage.</p><p>&nbsp;</p><p>* Patients with more rapid metabolism, clinically identified by higher than average dose requirements,</p><p>should receive a smaller dose more frequently to prevent breakthrough symptoms resulting from low</p><p>trough concentrations before the next dose. A reliably absorbed slow-release formulation will</p><p>decrease fluctuations and permit longer dosing intervals.</p><p>&nbsp;</p><p><strong>Table VI. Dosage adjustment guided by serum theophylline concentration.</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Peak Serum Concentration Dos age Adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;9.9 mcg/mL</p></td><td style="vertical-align:top"><p>If symptoms are not controlled and current dosage is tolerated, increase dose about 25%. Recheck serum concentration after three days for further dosage adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>10 to 14.9 mcg/mL</p></td><td style="vertical-align:top"><p>If symptoms are controlled and current dosage is tolerated, maintain dose and recheck serum concentration at 6-12 month intervals. If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen.</p></td></tr><tr><td style="vertical-align:top"><p>15-19.9 mcg/mL</p></td><td style="vertical-align:top"><p>Consider 10% decrease in dose to provide greater margin of safety even if current dosage is tolerated.</p></td></tr><tr><td style="vertical-align:top"><p>20-24.9 mcg/mL</p></td><td style="vertical-align:top"><p>Decrease dose by 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>25-30 mcg/mL</p></td><td style="vertical-align:top"><p>Skip next dose and decrease subsequent doses at least 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment. If symptomatic, consider whether overdose treatment is indicated (see recommendations for chronic overdosage).</p></td></tr><tr><td style="vertical-align:top"><p>&gt;30 mcg/mL</p></td><td style="vertical-align:top"><p>Treat overdose as indicated (see recommendations for chronic overdosage). If theophylline is subsequently resumed, decrease dose by at least 50% and recheck serum concentration after 3 days to guide further dosage adjustment.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dose reduction and/or serum theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce theophylline clearance occur (e.g., sustained fever), or a drug that interacts with theophylline is added or discontinued (see WARNINGS).</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Riaphyllin is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Concurrent Illness :</strong></p><p>Theophylline should be used with extreme caution in patients with the following clinical conditions due</p><p>to the increased risk of exacerbation of the concurrent condition:</p><ul><li>Active peptic ulcer disease</li><li>Seizure disorders</li><li>Cardiac arrhythmias (not including bradyarrhythmias)</li></ul><p><strong>Conditions That Reduce Theophylline Clearance:</strong></p><p>There are several readily identifiable causes of reduced theophylline clearance. <strong>If the total daily dose is not appropriately reduced in the presence of these risk factors , severe and potentially fatal theophylline toxicity can occur</strong>. Careful consideration must be given to the benefits and risks of<strong> </strong>theophylline use and the need for more intensive motoring of serum theophylline concentrations in<strong> </strong>patients with the following risk factors:</p><p><strong><u>Age</u></strong></p><ul><li>Neonates (term and premature)</li><li>Children &lt;1 year</li><li>Elderly (&gt;60 years)</li></ul><p><strong><u>Concurrent Diseases</u></strong></p><ul><li>Acute pulmonary edema</li><li>Congestive heart failure</li><li>Corpulmonale</li><li>Fever; &ge;102&deg;F for 24 hours or more; or lesser temperature elevations for longer periods</li><li>Hypothyroidism</li><li>Liver disease; cirrhosis, acute hepatitis</li><li>Reduced renal function in infants &lt;3 months of age</li><li>Sepsis with multi-organ failure</li><li>Shock</li></ul><p><strong><u>Cessation of Smoking</u></strong></p><p><strong><u>Drug Interactions</u></strong><strong> </strong>Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin,</p><p>tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (see PRECAUTIONS, Drug Interactions, Table II).</p><p><strong>When Signs or Symptoms of Theophylline Toxicity Are Present:</strong></p><p><strong>Whenever a patient receiving theophylline develops nausea or vomiting, particularly repetitive vomiting or other signs or symptoms cons is tent with theophylline toxicity (even if another cause may be suspected), additional doses of theophylline should be withheld and a serum theophylline concentration measured immediately</strong>. Patients should be instructed not to continue any dosage that<strong> </strong>causes adverse effects and to withhold subsequent doses until the symptoms have resolved, at which<strong> </strong>time the clinician may instruct the patient to resume the drug at a lower dosage (see DOSAGE AND<strong> </strong>ADMINISTRATION, Dosing Guidelines, Table VI).</p><p><strong>Dosage Increases :</strong></p><p>Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta - selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. A peak steady state serum theophylline concentration should be measured before increasing the dose in response to persistent chronic symptoms to ascertain whether an increase in dose is safe. Before increasing the theophylline dose on the basis of a low serum concentration, the clinician should consider whether the blood sample was obtained at an appropriate time in relationship to the dose and whether the patient has adhered to the prescribed regimen (see PRECAUTIONS, Laboratory Tests).</p><p>As the rate of theophylline clearance may be dose-dependent (i.e., steady-state serum concentrations</p><p>may increase disproportionately to the increase in dose), an increase in dose based upon a subtherapeutic</p><p>serum concentration measurement should be conservative. In general, limiting dose increases to about 25% of the previous total daily dose will reduce the risk of unintended excessive increases in serum theophylline concentration (see DOSAGE AND ADMINISTRATION, Table VI).</p><p><strong>PRECAUTIONS</strong></p><p><strong>&nbsp;</strong></p><p><strong>General:</strong></p><p>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy, prior to increases in theophylline dose, and during follow up (see WARNINGS). The dose of theophylline selected for initiation of therapy should be low and, if tolerated, increased slowly over a period of a week or longer with the final dose guided by monitoring serum theophylline concentrations and the patient&#39;s clinical response (see DOSAGE AND ADMINISTRATION, Table V).</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring Serum Theophylline Concentrations :</strong></p><p>Serum theophylline concentration measurements are readily available and should be used to determine whether the dosage is appropriate. Specifically, the serum theophylline concentration should be measured as follows:</p><p>1. When initiating therapy to guide final dosage adjustment after titration.</p><p>2. Before making a dose increase to determine whether the serum concentration is sub-therapeutic in a patient who continues to be symptomatic.</p><p>3. Whenever signs or symptoms of theophylline toxicity are present.</p><p>4. Whenever there is a new illness, worsening of a chronic illness or a change in the patient&#39;s treatment regimen that may alter theophylline clearance (e.g., fever &gt;102&deg;F sustained for 24 hours, hepatitis, or drugs listed in Table II are added or discontinued).</p><p>To guide a dose increase, the blood sample should be obtained at the time of the expected peak serum theophylline concentration; 1-2 hours after a dose at steady-state. For most patients, steady-state will be reached after 3 days of dosing when no doses have been missed, no extra doses have been added, and none of the doses have been taken at unequal intervals. A trough concentration (i.e., at the end of the dosing interval) provides no additional useful information and may lead to an inappropriate dose increase since the peak serum theophylline concentration can be two or more times greater than the trough concentration with an immediate-release formulation. If the serum sample is drawn more than two hours after the dose, the results must be interpreted with caution since the concentration may not be reflective of the peak concentration. In contrast, when signs or symptoms of theophylline toxicity are present, the serum sample should be obtained as soon as possible, analyzed immediately, and the result</p><p>reported to the clinician without delay. In patients in whom decreased serum protein binding is suspected (e.g., cirrhosis, women during the third trimester of pregnancy), the concentration of unbound theophylline should be measured and the dosage adjusted to achieve an unbound concentration of 6-12 mcg/mL.</p><p>Saliva concentrations of theophylline cannot be used reliably to adjust dosage without special techniques.</p><p><strong>&nbsp;</strong></p><p><strong>Effects on Laboratory Tests :</strong></p><p>As a result of its pharmacological effects, theophylline at serum concentrations within the 10-20 mcg/mL range modestly increases plasma glucose (from a mean of 88 mg% to 98 mg%), uric acid (from a mean of 4 mg/dl to 6 mg/dl), free fatty acids (from a mean of 451 &mu;eq/l to 800 &mu;eq/l), total cholesterol (from a mean of 140 vs 160 mg/dl), HDL (from a mean of 36 to 50 mg/dl), HDL/LDL ratio (from a mean of 0.5 to 0.7), and urinary free cortisol excretion (from a mean of 44 to 63 mcg/24 hr). Theophylline at serum concentrations within the 10-20 mcg/mL range may also transiently decrease serum concentrations of triiodothyronine (144 before, 131 after one week and 142 ng/dl after 4 weeks of theophylline). The clinical importance of these changes should be weighed against the potential therapeutic benefit of theophylline in individual patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs. The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the &ldquo;Effect&rdquo; column of Table II assumes that the interacting drug is being added to a steady-state theophylline</p><p>regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a drug that enhances theophylline clearance (e.g., rifampin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be larger. Discontinuation of a concomitant drug that increases theophylline clearance will result in accumulation of theophylline to potentially toxic levels, unless the theophylline dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits theophylline clearance will result in decreased serum theophylline concentrations, unless the theophylline dose is appropriately increased.</p><p>The drugs listed in Table III have either been documented not to interact with theophylline or do not produce a clinically significant interaction (i.e., &lt;15% change in theophylline clearance).</p><p>The listing of drugs in Table II and III are current as of February 9, 1995. New interactions are continuously being reported for theophylline, especially with new chemical entities. <strong>The clinician</strong> <strong>should not assume that a drug does not interact with theophylline if it is not listed in Table II</strong>.</p><p>Before addition of a newly available drug in a patient receiving theophylline, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and theophylline has been reported.</p><p><strong>Table II. Clinically significant drug interactions with theophylline .</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Drug</strong></p></td><td style="vertical-align:top"><p><strong>Type of Interaction</strong></p></td><td style="vertical-align:top"><p><strong>Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Adenosine</p></td><td style="vertical-align:top"><p>Theophylline blocks adenosine</p><p>receptors.</p></td><td style="vertical-align:top"><p>Higher doses of adenosine may be</p><p>required to achieve desired effect.</p></td></tr><tr><td style="vertical-align:top"><p>Alcohol</p></td><td style="vertical-align:top"><p>A single large dose of alcohol (3</p><p>ml/kg of whiskey) decreases</p><p>theophylline clearance for up to 24</p><p>hours.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>Allopurinol</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance at</p><p>allopurinol doses &gt;600 mg/day.</p></td><td style="vertical-align:top"><p>25% increase</p></td></tr><tr><td style="vertical-align:top"><p>Amino glutethimide</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>induction of microsomal enzyme</p><p>activity.</p></td><td style="vertical-align:top"><p>25% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p></td><td style="vertical-align:top"><p>Similar to aminoglutethimide.</p></td><td style="vertical-align:top"><p>30% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance by</p><p>inhibiting cytochrome P450 1A2.</p></td><td style="vertical-align:top"><p>70% increase</p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>Similar to cimetidine</p></td><td style="vertical-align:top"><p>40% increase</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin</p></td><td style="vertical-align:top"><p>Similar to erythromycin</p></td><td style="vertical-align:top"><p>25% increase</p></td></tr><tr><td style="vertical-align:top"><p>Diazepam</p></td><td style="vertical-align:top"><p>Benzodiazepines increase CNS</p><p>concentrations of adenosine, a potent</p><p>CNS depressant, while theophylline</p><p>blocks adenosine receptors.</p></td><td style="vertical-align:top"><p>Larger diazepam doses may be</p><p>required to produce desired level of</p><p>sedation. Discontinuation of</p><p>theophylline without reduction of</p><p>diazepam dose may result in</p><p>respiratory depression.</p></td></tr><tr><td style="vertical-align:top"><p>Disulfiram</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance by inhibiting hydroxylation and demethylation.</p></td><td style="vertical-align:top"><p>50% increase</p></td></tr><tr><td style="vertical-align:top"><p>Enoxacin</p></td><td style="vertical-align:top"><p>Similar to cimetidine.</p></td><td style="vertical-align:top"><p>300% increase</p></td></tr><tr><td style="vertical-align:top"><p>Ephedrine</p></td><td style="vertical-align:top"><p>Synergistic CNS effects</p></td><td style="vertical-align:top"><p>Increased frequency of nausea,</p><p>nervousness, and insomnia.</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p></td><td style="vertical-align:top"><p>Erythromycin metabolite decreases theophylline clearance by inhibiting</p><p>cytochrome P450 3A3.</p></td><td style="vertical-align:top"><p>35% increase. Erythromycin steady- state serum concentrations decrease</p><p>by a similar amount.</p></td></tr><tr><td style="vertical-align:top"><p>Estrogen</p></td><td style="vertical-align:top"><p>Estrogen containing oral</p><p>contraceptives decrease theophylline</p><p>clearance in a dose- dependent</p><p>fashion. The effect of progesterone</p><p>on theophylline clearance is unknown.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>Flurazepam</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr><tr><td style="vertical-align:top"><p>Fluvoxamine</p></td><td style="vertical-align:top"><p>Similar to cimetidine</p></td><td style="vertical-align:top"><p>Similar to cimetidine</p></td></tr><tr><td style="vertical-align:top"><p>Halothane</p></td><td style="vertical-align:top"><p>Halothane sensitizes the myocardium to catecholamines, theophylline increases release of endogenous catecholamines.</p></td><td style="vertical-align:top"><p>Increased risk of ventricular</p><p>arrhythmias.</p></td></tr><tr><td style="vertical-align:top"><p>Interferon, human</p><p>recombinant alpha-A</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>100% increase</p></td></tr><tr><td style="vertical-align:top"><p>Isoproterenol (IV)</p></td><td style="vertical-align:top"><p>Increases theophylline clearance.</p></td><td style="vertical-align:top"><p>20% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Ketamine</p></td><td style="vertical-align:top"><p>Pharmacologic</p></td><td style="vertical-align:top"><p>May lower theophylline seizure</p><p>threshold.</p></td></tr><tr><td style="vertical-align:top"><p>Lithium</p></td><td style="vertical-align:top"><p>Theophylline increases renal lithium</p><p>clearance.</p></td><td style="vertical-align:top"><p>Lithium dose required to achieve a</p><p>therapeutic serum concentration</p><p>increased an average of 60%.</p></td></tr><tr><td style="vertical-align:top"><p>Lorazepam</p></td><td style="vertical-align:top"><p>Similar to disulfiram</p></td><td style="vertical-align:top"><p>80% increase</p></td></tr><tr><td style="vertical-align:top"><p>Midazolam</p></td><td style="vertical-align:top"><p>Similar to diazepam</p></td><td style="vertical-align:top"><p>Similar to diazepam.</p></td></tr><tr><td style="vertical-align:top"><p>Moricizine</p></td><td style="vertical-align:top"><p>Increases theophylline clearance.</p></td><td style="vertical-align:top"><p>25% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Pancuronium</p></td><td style="vertical-align:top"><p>Theophylline may antagonize nondepolarizing</p><p>neuromuscular blocking effects; possibly due to</p><p>phosphodiesterase inhibition.</p></td><td style="vertical-align:top"><p>Larger dose of pancuronium may be</p><p>required to achieve neuromuscular</p><p>blockade.</p></td></tr><tr><td style="vertical-align:top"><p>Pentoxifylline</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>30% increase</p></td></tr><tr><td style="vertical-align:top"><p>Phenobarbital (PB)</p></td><td style="vertical-align:top"><p>Similar to aminoglutethimide.</p></td><td style="vertical-align:top"><p>25% decrease after two weeks of</p><p>concurrent PB.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Phenytoin increases theophylline clearance by increasing microsomal enzyme activity. Theophylline decreases phenytoin absorption.</p></td><td style="vertical-align:top"><p>Serum theophylline and phenytoin</p><p>concentrations decrease about 40%.</p></td></tr><tr><td style="vertical-align:top"><p>Propafenone</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance and</p><p>pharmacologic interaction.</p></td><td style="vertical-align:top"><p>40% increase. Beta-2 blocking effect</p><p>may decrease efficacy of theophylline.</p></td></tr><tr><td style="vertical-align:top"><p>Propranolol</p></td><td style="vertical-align:top"><p>Similar to cimetidine and</p><p>pharmacologic interaction.</p></td><td style="vertical-align:top"><p>100% increase. Beta-2 blocking effect may decrease efficacy of theophylline.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by increasing cytochrome P450 1A2 and 3A3 activity.</p></td><td style="vertical-align:top"><p>20-40% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Sulfinpyrazone</p></td><td style="vertical-align:top"><p>Increases theophylline clearance by</p><p>increasing demethylation and hydroxylation. Decreases renal clearance of theophylline.</p></td><td style="vertical-align:top"><p>20% decrease</p></td></tr><tr><td style="vertical-align:top"><p>Tacrine</p></td><td style="vertical-align:top"><p>Similar to cimetidine, also increases</p><p>renal clearance of theophylline.</p></td><td style="vertical-align:top"><p>90% increase</p></td></tr><tr><td style="vertical-align:top"><p>Thiabendazole</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>190% increase</p></td></tr><tr><td style="vertical-align:top"><p>Ticlopidine</p></td><td style="vertical-align:top"><p>Decreases theophylline clearance.</p></td><td style="vertical-align:top"><p>60% increase</p></td></tr><tr><td style="vertical-align:top"><p>Troleandomycin</p></td><td style="vertical-align:top"><p>Similar to erythromycin.</p></td><td style="vertical-align:top"><p>33-100% increase depending on</p><p>troleandomycin dose.</p></td></tr><tr><td style="vertical-align:top"><p>Verapamil</p></td><td style="vertical-align:top"><p>Similar to disulfiram.</p></td><td style="vertical-align:top"><p>20% increase</p></td></tr></tbody></table><p>*Refer to PRECAUTIONS, Drug Interactions for further information regarding table.</p><p><strong>&nbsp;</strong></p><p><strong>Table III. Drugs that have been documented not to interact with theophylline or drugs that</strong></p><p><strong>produce no clinically significant interaction with theophylline.*</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>albuterol</p></td><td style="vertical-align:top"><p>systemic and inhaled mebendazole</p></td></tr><tr><td style="vertical-align:top"><p>amoxicillin</p></td><td style="vertical-align:top"><p>amoxicillin</p></td></tr><tr><td style="vertical-align:top"><p>ampicillin</p></td><td style="vertical-align:top"><p>with or without sulbactam methylprednisolone</p></td></tr><tr><td style="vertical-align:top"><p>atenolol</p></td><td style="vertical-align:top"><p>metronidazole</p></td></tr><tr><td style="vertical-align:top"><p>azithromycin</p></td><td style="vertical-align:top"><p>metoprolol</p></td></tr><tr><td style="vertical-align:top"><p>Caffeine, dietary ingestion</p></td><td style="vertical-align:top"><p>nadolol</p></td></tr><tr><td style="vertical-align:top"><p>cefactor</p></td><td style="vertical-align:top"><p>nifedipine</p></td></tr><tr><td style="vertical-align:top"><p>co-trimoxazole (trimethoprim and sulfamethoxazole)</p></td><td style="vertical-align:top"><p>nizatidine</p></td></tr><tr><td style="vertical-align:top"><p>diltiazem</p></td><td style="vertical-align:top"><p>norfloxacin</p></td></tr><tr><td style="vertical-align:top"><p>dirithromycin</p></td><td style="vertical-align:top"><p>ofloxacin</p></td></tr><tr><td style="vertical-align:top"><p>enflurane</p></td><td style="vertical-align:top"><p>omeprazole</p></td></tr><tr><td style="vertical-align:top"><p>famotidine</p></td><td style="vertical-align:top"><p>prednisone, prednisolone</p></td></tr><tr><td style="vertical-align:top"><p>felodipine</p></td><td style="vertical-align:top"><p>ranitidine</p></td></tr><tr><td style="vertical-align:top"><p>finasteride</p></td><td style="vertical-align:top"><p>rifabutin</p></td></tr><tr><td style="vertical-align:top"><p>hydrocortisone</p></td><td style="vertical-align:top"><p>roxithromycin</p></td></tr><tr><td style="vertical-align:top"><p>isoflurane</p></td><td style="vertical-align:top"><p>isoflurane sorbitol (purgative doses do not inhibit theophylline absorption)</p></td></tr><tr><td style="vertical-align:top"><p>isoniazid sucralfate</p></td><td style="vertical-align:top"><p>isoniazid sucralfate</p></td></tr><tr><td style="vertical-align:top"><p>isradipine</p></td><td style="vertical-align:top"><p>terbutaline, systemic</p></td></tr><tr><td style="vertical-align:top"><p>influenza vaccine</p></td><td style="vertical-align:top"><p>terfenadine</p></td></tr><tr><td style="vertical-align:top"><p>ketoconazole</p></td><td style="vertical-align:top"><p>tetracycline</p></td></tr><tr><td style="vertical-align:top"><p>lomefloxacin</p></td><td style="vertical-align:top"><p>tocainide</p></td></tr></tbody></table><p>&nbsp;</p><p>* Refer to PRECAUTIONS, Drug Interactions for information regarding table.</p><p><strong>&nbsp;</strong></p><p><strong>The Effect of Other Drugs on Theophylline Serum Concentration Measurements :</strong></p><p>Most serum theophylline assays in clinical use are immunoassays which are specific for theophylline.</p><p>Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some</p><p>drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and</p><p>xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry</p><p>reagent office methods to be higher than the actual serum theophylline concentration.</p><p><strong>Carcinogenesis , Mutagenesis , and Impairment of Fertility:</strong></p><p>Long term carcinogenicity studies have been carried out in mice (oral doses 30-150 mg/kg) and rats (oral doses 5-75mg/kg). Results are pending.</p><p>Theophylline has been studied in Ames salmonella, <em>in vivo </em>and <em>in vitro </em>cytogenetics, micronucleus and</p><p>Chinese hamster ovary test systems and has not been shown to be genotoxic.</p><p>In a 14 week continuous breeding study, theophylline, administered to mating pairs of B6C3F1 mice at</p><p>oral doses of 120, 270 and 500 mg/kg (approximately 1.0-3.0 times the human dose on a mg/m basis)</p><p>impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean</p><p>number of litters per fertile pair, and increases in the gestation period at the high dose as well as</p><p>decreases in the proportion of pups born alive at the mid and high dose.</p><p>In 13 week toxicity studies, theophylline was administered to F344 rats and B6C3F1 mice at oral doses</p><p>of 40-300 mg/kg (approximately 2.0 times the human dose on a mg/m basis). At the high dose,</p><p>systemic toxicity was observed in both species including decreases in testicular weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy :</strong></p><p>Category C</p><p>There are no adequate and well controlled studies in pregnant women. Additionally, there are no teratogenicity studies in non-rodents (e.g., rabbits). Theophylline was not shown to be teratogenic in CD-1 mice at oral doses up to 400 mg/kg, approximately 2.0 times the human dose on a mg/m2 basis or in CD-1 rats at oral doses up to 260 mg/kg, approximately 3.0 times the recommended human dose on a mg/m basis. At a dose of 220 mg/kg, embryotoxicity was observed in rats in the absence of maternal toxicity.</p><p>&nbsp;</p><p><strong>Breast Feeding :</strong></p><p>Theophylline is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. The concentration of theophylline in breast milk is about equivalent to the maternal serum concentration. An infant ingesting a liter of breast milk containing 10-20 mcg/mL of theophylline per day is likely to receive 10-20 mg of theophylline per day. Serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Riaphyllin &nbsp;have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are &lt;20 mcg/ mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE). The transient caffeine-like adverse reactions occur in about 50% of patients when theophylline therapy is initiated at doses higher than recommended initial doses (e.g., &gt;300 mg/day in adults and &gt;12 mg/kg/day in children beyond &gt;1 year of age). During the initiation of theophylline therapy, caffeine-like adverse effects may transiently alter patient behavior, especially in school age children, but this response rarely</p><p>persists. Initiation of theophylline therapy at a low dose with subsequent slow titration to a predetermined age-related maximum dose will significantly reduce the frequency of these transient adverse effects (see DOSAGE AND ADMINISTRATION, Table V). In a small percentage of patients (&lt;3% of children and &lt;10% of adults) the caffeine-like adverse effects persist during maintenance therapy, even at peak serum theophylline concentrations within the therapeutic range (i.e., 10-20 mcg/mL). Dosage reduction may alleviate the caffeine-like adverse effects in these patients, however, persistent adverse effects should result in a reevaluation of the need for continued theophylline therapy and the potential therapeutic benefit of alternative treatment.</p><p>Other adverse reactions that have been reported at serum theophylline concentrations &lt;20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations 15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations &lt;20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations &lt;20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations &lt;20 mcg/mL</p><p>have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).</p><p>&nbsp;</p><p><strong>Table IV. Manifestations of theophylline toxicity.*</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Percentage of patients reported with sign or symptom</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Acute Overdose</strong></p><p><strong>(Large Single Ingestion)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Chronic Overdosage</strong></p><p><strong>(Multiple Excessive Doses )</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Sign/Symptom</strong></p></td><td style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>(n=157)</strong></p></td><td style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>(n=14)</strong></p></td><td style="vertical-align:top"><p><strong>Study 1</strong></p><p><strong>(n=92)</strong></p></td><td style="vertical-align:top"><p><strong>Study 2</strong></p><p><strong>(n=102)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Asymptomatic</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>73</p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>61</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Hematemesis</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic/Other</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>43</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>98</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Acid/base disturbance</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Rhabdomyolysis</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sinus tachycardia</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>62</p></td></tr><tr><td style="vertical-align:top"><p>Other supraventricular</p><p>tachycardias</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Ventricular premature beats</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>Atrial fibrillation or flutter</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Multifocal atrial</p><p>tachycardia</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Ventricular arrhythmias</p><p>with</p><p>hemodynamic instability</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension/shock</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Neurologic</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervousness</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Tremors</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Disorientation</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Seizures</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4</p></td></tr></tbody></table><p>&nbsp;</p><p>*These data are derived from two studies in patients with serum theophylline concentrations &gt;30 mcg/mL. In the</p><p>first study (Study #1 - Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 24 9</p><p>consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second</p><p>study (Study #2 - Sessler, Am J Med 1990;88:567-76), data were retrospectively collected from 116 cases with</p><p>serum theophylline concentrations &gt;30 mcg/mL among 6000 blood samples obtained for measurement of serum</p><p>theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of</p><p>theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in</p><p>Study #1, 4 8% of the patients had acute intoxications versus only 10% in Study #2) and different methods of</p><p>reporting results.</p><p>&nbsp;</p><p><strong>To report any side effects</strong></p><p>- National Pharmacovigilance and Drug Safety Center (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- To call the executive management of vigilance and crisis management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 2340</p><p>- Toll-free: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General:</strong></p><p>The chronicity and pattern of theophylline overdosage significantly influences clinical manifestations</p><p>of toxicity, management and outcome. There are two common presentations: (1) <em>acute overdose</em>, <em>i.e.</em>,</p><p>ingestion of a single large excessive dose (&gt;10 mg/kg) as occurs in the context of an attempted suicide</p><p>or isolated medication error, and (2) <em>chronic overdosage, i.e.</em>, ingestion of repeated doses that are</p><p>excessive for the patient&#39;s rate of theophylline clearance. The most common causes of chronic</p><p>theophylline overdosage include patient or care giver error in dosing, clinician prescribing of an</p><p>excessive dose or a normal dose in the presence of factors known to decrease the rate of theophylline</p><p>clearance, and increasing the dose in response to an exacerbation of symptoms without first measuring</p><p>the serum theophylline concentration to determine whether a dose increase is safe.</p><p>Severe toxicity from theophylline overdose is a relatively rare event. In one health maintenance</p><p>organization, the frequency of hospital admissions for chronic overdosage of theophylline was about 1</p><p>per 1000 person-years exposure. In another study, among 6000 blood samples obtained for</p><p>measurement of serum theophylline concentration, for any reason, from patients treated in an emergency</p><p>department, 7% were in the 20-30 mcg/mL range and 3% were &gt;30 mcg/mL. Approximately two-thirds</p><p>of the patients with serum theophylline concentrations in the 20-30 mcg/mL range had one or more</p><p>manifestations of toxicity while &gt;90% of patients with serum theophylline concentrations &gt;30mcg/mL</p><p>were clinically intoxicated. Similarly, in other reports, serious toxicity from theophylline is seen</p><p>principally at serum concentrations &gt;30 mcg/mL.</p><p>Several studies have described the clinical manifestations of theophylline overdose and attempted to</p><p>determine the factors that predict life-threatening toxicity. In general, patients who experience an acute</p><p>overdose are less likely to experience seizures than patients who have experienced a chronic</p><p>overdosage, unless the peak serum theophylline concentration is &gt;100 mcg/mL. After a chronic</p><p>overdosage, generalized seizures, life-threatening cardiac arrhythmias, and death may occur at serum</p><p>theophylline concentrations &gt;30 mcg/mL. The severity of toxicity after chronic overdosage is more</p><p>strongly correlated with the patient&#39;s age than the peak serum theophylline concentration; patients &gt;60</p><p>years are at the greatest risk for severe toxicity and mortality after a chronic overdosage. Pre-existing</p><p>or concurrent disease may also significantly increase the susceptibility of a patient to a particular toxic</p><p>manifestation, e.g., patients with neurologic disorders have an increased risk of seizures and patients</p><p>with cardiac disease have an increased risk of cardiac arrhythmias for a given serum theophylline</p><p>concentration compared to patients without the underlying disease.</p><p>The frequency of various reported manifestations of theophylline overdose according to the mode of</p><p>overdose are listed in Table IV. Other manifestations of theophylline toxicity include increases in</p><p>serum calcium, creatine kinase, myoglobin and leukocyte count, decreases in serum phosphate and</p><p>magnesium, acute myocardial infarction, and urinary retention in men with obstructive uropathy. Seizures</p><p>associated with serum theophylline concentrations &gt;30 mcg/mL are often resistant to anticonvulsant</p><p>therapy and may result in irreversible brain injury if not rapidly controlled. Death from theophylline</p><p>toxicity is most often secondary to cardiorespiratory arrest and/or hypoxic encephalopathy following</p><p>prolonged generalized seizures or intractable cardiac arrhythmias causing hemodynamic compromise.</p><p>&nbsp;</p><p><strong>Overdose Management:</strong></p><p><strong><u>General Recommendations for Patients with Symptoms of Theophylline Overdose or Serum</u></strong></p><p><strong><u>Theophylline Concentrations &gt;30 mcg/mL (Note: Serum theophylline concentrations may</u></strong></p><p><strong><u>continue to increase after presentation of the patient for medical care.)</u></strong></p><p>1. While simultaneously instituting treatment, contact a regional poison center to obtain updated</p><p>information and advice on individualizing the recommendations that follow.</p><p>2. Institute supportive care, including establishment of intravenous access, maintenance of the airway,</p><p>and electrocardiographic monitoring.</p><p>3. <u>Treatment of seizures</u> Because of the high morbidity and mortality associated with theophyllineinduced</p><p>seizures, treatment should be rapid and aggressive. Anticonvulsant therapy should be initiated</p><p>with an intravenous benzodiazepine, e.g., diazepam, in increments of 0.1-0.2 mg/kg every 1-3 minutes</p><p>until seizures are terminated. Repetitive seizures should be treated with a loading dose of phenobarbital</p><p>(20 mg/kg infused over 30-60 minutes). Case reports of theophylline overdose in humans and animal</p><p>studies suggest that phenytoin is ineffective in terminating theophylline-induced seizures. The doses of</p><p>benzodiazepines and phenobarbital required to terminate theophylline-induced seizures are close to the</p><p>doses that may cause severe respiratory depression or respiratory arrest; the clinician should therefore</p><p>be prepared to provide assisted ventilation. Elderly patients and patients with COPD may be more</p><p>susceptible to the respiratory depressant effects of anticonvulsants. Barbiturate-induced coma or</p><p>administration of general anesthesia may be required to terminate repetitive seizures or status</p><p>epilepticus. General anesthesia should be used with caution in patients with theophylline overdose</p><p>because fluorinated volatile anesthetics may sensitize the myocardium to endogenous catecholamines</p><p>released by theophylline. Enflurane appears to less likely to be associated with this effect than</p><p>halothane and may, therefore, be safer. Neuromuscular blocking agents alone should not be used to</p><p>terminate seizures since they abolish the musculoskeletal manifestations without terminating seizure</p><p>activity in the brain.</p><p>4. <u>Anticipate Need for Anticonvulsants</u> In patients with theophylline overdose who are at high risk for</p><p>theophylline induced seizures, e.g., patients with acute overdoses and serum theophylline</p><p>concentrations &gt;100 mcg/mL chronic overdosage in patients &gt;60 years of age with serum theophylline</p><p>concentrations &gt;30 mcg/mL, the need for anticonvulsant therapy should be anticipated. A benzodiazepine</p><p>such as diazepam should be drawn into a syringe and kept at the patient&#39;s bedside and medical personnel</p><p>qualified to treat seizures should be immediately available. In selected patients at high risk for</p><p>theophylline-induced seizures, consideration should be given to the administration of prophylactic</p><p>anticonvulsant therapy. Situations where prophylactic anticonvulsant therapy should be considered in</p><p>high risk patients include anticipated delays in instituting methods for extracorporeal removal of</p><p>theophylline (e.g., transfer of a high risk patient from one health care facility to another for</p><p>extracorporeal removal) and clinical circumstances that significantly interfere with efforts to enhance</p><p>theophylline clearance (e.g., a neonate where dialysis may not be technically feasible or a patient with</p><p>vomiting unresponsive to antiemetics who is unable to tolerate multiple-dose oral activated charcoal). In</p><p>animal studies, prophylactic administration of phenobarbital, but not phenytoin, has been shown to delay</p><p>the onset of theophylline induced generalized seizures and to increase the dose of theophylline</p><p>required to induce seizures (i.e., markedly increases the LD50). Although there are no controlled</p><p>studies in humans, a loading dose of intravenous Phenobarbital (20 mg/kg infused over 60 minutes) may</p><p>delay or prevent life-threatening seizures in high risk patients while efforts to enhance theophylline</p><p>clearance are continued. Phenobarbital may cause respiratory depression, particularly in elderly patients</p><p>and patients with COPD.</p><p>5. <u>Treatment of cardiac arrhythmias</u> Sinus tachycardia and simple ventricular premature beats are not</p><p>harbingers of life-threatening arrhythmias, they do not require treatment in the absence of hemodynamic</p><p>compromise, and they resolve with declining serum theophylline concentrations. Other arrhythmias,</p><p>especially those associated with hemodynamic compromise, should be treated with antiarrhythmic</p><p>therapy appropriate for the type of arrhythmia.</p><p>6. <u>Gastrointestinal decontamination</u> Oral activated charcoal (0.5 g/kg up to 20 g and repeat at least once</p><p>1-2 hours after the first dose) is extremely effective in blocking the absorption of theophylline</p><p>throughout the gastrointestinal tract, even when administered several hours after ingestion. If the patient</p><p>is vomiting, the charcoal should be administered through a nasogastric tube or after administration of an</p><p>antiemetic. Phenothiazine antiemetics such as prochlorperazine or perphenazine should be avoided</p><p>since they can lower the seizure threshold and frequently cause dystonic reactions. A single dose of</p><p>sorbitol may be used to promote stooling to facilitate removal of theophylline bound to charcoal from</p><p>the gastrointestinal tract. Sorbitol, however, should be dosed with caution since it is a potent purgative</p><p>which can cause profound fluid and electrolyte abnormalities, particularly after multiple doses.</p><p>Commercially available fixed combinations of liquid charcoal and sorbitol should be avoided in young</p><p>children and after the first dose in adolescents and adults since they do not allow for individualization of</p><p>charcoal and sorbitol dosing. Ipecac syrup should be avoided in theophylline overdoses. Although</p><p>ipecac induces emesis, it does not reduce the absorption of theophylline unless administered within 5</p><p>minutes of ingestion and even then is less effective than oral activated charcoal. Moreover, ipecac</p><p>induced emesis may persist for several hours after a single dose and significantly decrease the retention</p><p>and the effectiveness of oral activated charcoal.</p><p>7. <u>Serum Theophylline Concentration Monitoring</u> The serum theophylline concentration should be</p><p>measured immediately upon presentation, 2-4 hours later, and then at sufficient intervals, e.g., every 4</p><p>hours, to guide treatment decisions and to assess the effectiveness of therapy. Serum theophylline</p><p>concentrations may continue to increase after presentation of the patient for medical care as a result of</p><p>continued absorption of theophylline from the gastrointestinal tract. Serial monitoring of serum</p><p>theophylline serum concentrations should be continued until it is clear that the concentration is no</p><p>longer rising and has returned to non-toxic levels.</p><p>8<u>. General Monitoring Procedures</u> Electrocardiographic monitoring should be initiated on presentation</p><p>and continued until the serum theophylline level has returned to a non-toxic level. Serum electrolytes</p><p>and glucose should be measured on presentation and at appropriate intervals indicated by clinical</p><p>circumstances. Fluid and electrolyte abnormalities should be promptly corrected. Monitoring and</p><p>treatment should be continued until the serum concentration decreases below 20 mcg/mL.</p><p>9. <u>Enhance clearance of theophylline</u> Multiple-dose oral activated charcoal (e.g., 0.5 mg/kg up to 20 g,</p><p>every two hours) increases the clearance of theophylline at least twofold by adsorption of theophylline</p><p>secreted into gastrointestinal fluids. Charcoal must be retained in, and pass through, the gastrointestinal</p><p>tract to be effective; emesis should therefore be controlled by administration of appropriate antiemetics.</p><p>Alternatively, the charcoal can be administered continuously through a nasogastric tube in conjunction</p><p>with appropriate antiemetics. A single dose of sorbitol may be administered with the activated charcoal</p><p>to promote stooling to facilitate clearance of the adsorbed theophylline from the gastrointestinal tract.</p><p>Sorbitol alone does not enhance clearance of theophylline and should be dosed with caution to prevent</p><p>excessive stooling which can result in severe fluid and electrolyte imbalances. Commercially available</p><p>fixed combinations of liquid charcoal and sorbitol should be avoided in young children and after the</p><p>first dose in adolescents and adults since they do not allow for individualization of charcoal and</p><p>sorbitol dosing. In patients with intractable vomiting, extracorporeal methods of theophylline removal</p><p>should be instituted (see OVERDOSAGE, Extracorporeal Removal).</p><p><strong>Specific Recommendations </strong>:</p><p><strong>Acute Overdose</strong></p><p><u>A. Serum Concentration &gt;20&lt;30 mcg/mL</u></p><p>1. Administer a single dose of oral activated charcoal.</p><p>2. Monitor the patient and obtain a serum theophylline concentration in 2-4 hours to insure that the concentration is not increasing.</p><p>&nbsp;</p><p><u>B. Serum Concentration &gt;30&lt;100 mcg/mL</u></p><p>1. Administer multiple dose oral activated charcoal and measures to control emesis.</p><p>2. Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p>3. Institute extracorporeal removal if emesis, seizures, or cardiac arrhythmias cannot be adequately controlled (see OVERDOSAGE, Extracorporeal Removal).<br /></p><p><u>&nbsp;C. Serum Concentration &gt;100 mcg/mL</u></p><p>1. Consider prophylactic anticonvulsant therapy.</p><p>2. Administer multiple-dose oral activated charcoal and measures to control emesis.</p><p>3. Consider extracorporeal removal, even if the patient has not experienced a seizure (see OVERDOSAGE, Extracorporeal Removal).</p><p>4. Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p><strong>Chronic Overdosage</strong></p><p><u>A. Serum Concentration &gt;20&lt;30 mcg/mL (with manifestations of theophylline toxicity)</u></p><p>1. Administer a single dose of oral activated charcoal.</p><p>2. Monitor the patient and obtain a serum theophylline concentration in 2-4 hours to insure that the concentration is not increasing.</p><p><u>B. Serum Concentration &gt;30 mcg/mL in patients &lt;60 years of age</u></p><p>1. Administer multiple-dose oral activated charcoal and measures to control emesis.</p><p>2. Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p>3. Institute extracorporeal removal if emesis, seizures, or cardiac arrhythmias cannot be adequately controlled (see OVERDOSAGE, Extracorporeal Removal).</p><p><u>C. Serum Concentration &gt;30 mcg/mL in patients &ge;60 years of age.</u></p><p>1. Consider prophylactic anticonvulsant therapy.</p><p>2. Administer multiple-dose oral activated charcoal and measures to control emesis.</p><p>3. Consider extracorporeal removal even if the patient has not experienced a seizure (see OVERDOSAGE, Extracorporeal Removal).</p><p>4. Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</p><p><strong>&nbsp;</strong></p><p><strong>Extracorporeal Removal:</strong></p><p>Increasing the rate of theophylline clearance by extracorporeal methods may rapidly decrease serum concentrations, but the risks of the procedure must be weighed against the potential benefit. Charcoal hemoperfusion is the most effective method of extracorporeal removal, increasing theophylline clearance up to six fold, but serious complications, including hypotension, hypocalcemia, platelet consumption and bleeding diatheses may occur. Hemodialysis is about as efficient as multiple-dose oral activated charcoal and has a lower risk of serious complications than charcoal hemoperfusion.</p><p>Hemodialysis should be considered as an alternative when charcoal hemoperfusion is not feasible and multiple-dose oral charcoal is ineffective because of intractable emesis. Serum theophylline concentrations may rebound 5-10 mcg/mL after discontinuation of charcoal hemoperfusion or hemodialysis due to redistribution of theophylline from the tissue compartment. Peritoneal dialysis is ineffective for theophylline removal; exchange transfusions in neonates have been minimally effective.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: drugs for obstructive airway disease. ATC code: R03DA04.</p><p><strong>Mechanis m of Action:</strong></p><p>Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).</p><p>Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.</p><p>&nbsp;</p><p><strong>Serum Concentration-Effect Relations hip:</strong></p><p>Bronchodilation occurs over the serum theophylline concentration range of 5-20 mcg/mL. Clinically important improvement in symptom control has been found in most studies to require peak serum theophylline concentrations &gt;10 mcg/mL, but patients with mild disease may benefit from lower concentrations. At serum theophylline concentrations &gt;20mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining peak serum theophylline concentrations between 10 and 15 mcg/mL will achieve most of the drug&#39;s potential therapeutic benefit while minimizing the risk of serious adverse events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Overview </strong>Theophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form. Theophylline does not undergo any appreciable presystemic elimination, distributes freely into fat-free tissues and is extensively metabolized in the liver.</p><p>The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology (see Table I) and co-administration of other drugs (see Table II) can significantly alter the pharmacokinetic characteristics of theophylline. Within-subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients (e.g., at 24-hour intervals) and periodically in patients receiving long-term therapy, e.g., at 6-12 month intervals. More frequent measurements should be made in the presence of any condition that may significantly alter theophylline clearance (see PRECAUTIONS, Laboratory tests).</p><p>&nbsp;</p><p><strong>Table I. Mean and range of total body clearance and half-life of theophylline related to age and</strong></p><p><strong>altered physiological states .</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Population characteristics</strong></p></td><td style="vertical-align:top"><p><strong>Total body clearance*</strong></p><p><strong>mean (range)</strong></p><p><strong>(mL/kg/min)</strong></p></td><td style="vertical-align:top"><p><strong>Half-life</strong></p><p><strong>mean (range)</strong></p><p><strong>(hr)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Premature neonates</u></p><p>postnatal age 3-15 days</p></td><td style="vertical-align:top"><p>0.29 (0.09-0.49)</p></td><td style="vertical-align:top"><p>30 (17-43)</p></td></tr><tr><td style="vertical-align:top"><p>postnatal age 25-57 days</p></td><td style="vertical-align:top"><p>0.64 (0.04-1.2)</p></td><td style="vertical-align:top"><p>20 (9.4-30.6)</p></td></tr><tr><td style="vertical-align:top"><p><u>Term infants</u></p><p>postnatal age 1-2 days</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>25.7 (25-26.5)</p></td></tr><tr><td style="vertical-align:top"><p>postnatal age 3-30 weeks</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>11 (6-29)</p></td></tr><tr><td style="vertical-align:top"><p>Children</p><p>1-4 years</p></td><td style="vertical-align:top"><p>1.7 (0.5-2.9)</p></td><td style="vertical-align:top"><p>3.4 (1.2-5.6)</p></td></tr><tr><td style="vertical-align:top"><p>4-12 years</p></td><td style="vertical-align:top"><p>1.6 (0.8-2.4)</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>13-15 years</p></td><td style="vertical-align:top"><p>0.9 (0.48-1.3)</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>16-17 years</p></td><td style="vertical-align:top"><p>1.4 (0.2-2.6)</p></td><td style="vertical-align:top"><p>3.7 (1.5-5.9)</p></td></tr><tr><td style="vertical-align:top"><p><u>Adults (16-60 years)</u></p><p>otherwise healthy</p><p>non-smoking asthmatics</p></td><td style="vertical-align:top"><p>0.65 (0.27-1.03)</p></td><td style="vertical-align:top"><p>8.7 (6.1-12.8)</p></td></tr><tr><td style="vertical-align:top"><p>Elderly (&gt;60 years)</p><p>non-smokers with normal cardiac, liver, and</p><p>renal function</p></td><td style="vertical-align:top"><p>0.41 (0.21-0.61)</p></td><td style="vertical-align:top"><p>9.8 (1.6-18)</p></td></tr><tr><td style="vertical-align:top"><p><u>Concurrent illness or altered physiological state </u></p><p>Acute pulmonary edema</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.33 (0.07-2.45)</p></td><td style="vertical-align:top"><p>19 (3.1-82)</p></td></tr><tr><td style="vertical-align:top"><p>COPD-&gt;60 years, stable</p><p>non-smoker &gt;1 year</p></td><td style="vertical-align:top"><p>0.54 (0.44-0.64)</p></td><td style="vertical-align:top"><p>11 (9.4-12.6)</p></td></tr><tr><td style="vertical-align:top"><p>COPD with cor pulmonale</p></td><td style="vertical-align:top"><p>0.48 (0.08-0.88)</p></td><td style="vertical-align:top"><p>NR</p></td></tr><tr><td style="vertical-align:top"><p>Cystic fibrosis (14-28 years)</p></td><td style="vertical-align:top"><p>1.25 (0.31-2.2)</p></td><td style="vertical-align:top"><p>6.0 (1.8-10.2)</p></td></tr><tr><td style="vertical-align:top"><p>Fever associated with acute viral</p><p>respiratory illness (children 9-15 years)</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>7.0 (1.0-13)</p></td></tr><tr><td style="vertical-align:top"><p>Liver disease &ndash; cirrhosis</p></td><td style="vertical-align:top"><p>0.31 (0.1-0.7)</p></td><td style="vertical-align:top"><p>32 (10-56)</p></td></tr><tr><td style="vertical-align:top"><p>acute hepatitis</p></td><td style="vertical-align:top"><p>0.35 (0.25-0.45)</p></td><td style="vertical-align:top"><p>19.2 (16.6-21.8)</p></td></tr><tr><td style="vertical-align:top"><p>cholestasis</p></td><td style="vertical-align:top"><p>0.65 (0.25-1.45)</p></td><td style="vertical-align:top"><p>14.4 (5.7-31.8)</p></td></tr><tr><td style="vertical-align:top"><p>Pregnancy - 1st trimester</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>8.5 (3.1-13.9)</p></td></tr><tr><td style="vertical-align:top"><p>2nd trimester</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>8.8 (3.8-13.8)</p></td></tr><tr><td style="vertical-align:top"><p>3rd trimester</p></td><td style="vertical-align:top"><p>NR</p></td><td style="vertical-align:top"><p>13.0 (8.4-17.6)</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis with multi-organ failure</p></td><td style="vertical-align:top"><p>0.47 (0.19-1.9)</p></td><td style="vertical-align:top"><p>18.8 (6.3-24.1)</p></td></tr><tr><td style="vertical-align:top"><p>Thyroid disease - hypothyroid</p></td><td style="vertical-align:top"><p>0.38 (0.13-0.57)</p></td><td style="vertical-align:top"><p>11.6 (8.2-25)</p></td></tr><tr><td style="vertical-align:top"><p>hyperthyroid</p></td><td style="vertical-align:top"><p>0.8 (0.68-0.97)</p></td><td style="vertical-align:top"><p>4.5 (3.7-5.6)</p></td></tr></tbody></table><p>* Clearance represents the volume of blood completely cleared of theophylline by the liver in one minute. Values</p><p>listed were generally determined at serum theophylline concentrations &lt;20 mcg/mL; clearance may decrease and</p><p>half-life may increase at higher serum concentrations due to non-linear pharmacokinetics.</p><p>NR = not reported or not reported in a comparable format.</p><p>&nbsp;</p><p><strong>Note: </strong>In addition to the factors listed above, theophylline clearance is increased and half-life decreased</p><p>by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled</p><p>beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of</p><p>theophylline.</p><p><strong>&nbsp;</strong></p><p><strong>Absorption </strong></p><p>Theophylline is rapidly and completely absorbed after oral administration in solution or</p><p>immediate-release solid oral dosage form. After a single dose of 5 mg/kg in adults, a mean peak serum</p><p>concentration of about 10 mcg/mL (range 5-15 mcg/mL) can be expected 1-2 hr after the dose. Coadministration</p><p>of theophylline with food or antacids does not cause clinically significant changes in the</p><p>absorption of theophylline from immediate-release dosage forms.</p><p><strong>&nbsp;</strong></p><p><strong>Distribution </strong></p><p>Once theophylline enters the systemic circulation, about 40% is bound to plasma protein,</p><p>primarily albumin. Unbound theophylline distributes throughout body water, but distributes poorly into</p><p>body fat. The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7</p><p>L/kg) based on ideal body weight. Theophylline passes freely across the placenta, into breast milk and</p><p>into the cerebrospinal fluid (CSF). Saliva theophylline concentrations approximate unbound serum</p><p>concentrations, but are not reliable for routine or therapeutic monitoring unless special techniques are</p><p>used. An increase in the volume of distribution of theophylline, primarily due to reduction in plasma</p><p>protein binding, occurs in premature neonates, patients with hepatic cirrhosis, uncorrected acidemia, the</p><p>elderly and in women during the third trimester of pregnancy. In such cases, the patient may show signs</p><p>of toxicity at total (bound + unbound) serum concentrations of theophylline in the therapeutic range (10-</p><p>20 mcg/mL) due to elevated concentrations of the pharmacologically active unbound drug. Similarly, a</p><p>patient with decreased theophylline binding may have a subtherapeutic total drug concentration while</p><p>the pharmacologically active unbound concentration is in the therapeutic range. If only total serum</p><p>theophylline concentration is measured, this may lead to an unnecessary and potentially dangerous dose</p><p>increase. In patients with reduced protein binding, measurement of unbound serum theophylline</p><p>concentration provides a more reliable means of dosage adjustment than measurement of total serum</p><p>theophylline concentration. Generally, concentrations of unbound theophylline should be maintained in</p><p>the range of 6-12 mcg/mL.</p><p>Clearance represents the volume of blood completely cleared of theophylline by the liver in one minute. Values</p><p>listed were generally determined at serum theophylline concentrations &lt;20 mcg/mL; clearance may decrease and</p><p>half-life may increase at higher serum concentrations due to non-linear pharmacokinetics.</p><p>Reported range or estimated range (mean &plusmn; 2 SD) where actual range not reported.</p><p>NR = not reported or not reported in a comparable format.</p><p><strong>&nbsp;</strong></p><p><strong>Metabolism </strong></p><p>Following oral dosing, theophylline does not undergo any measurable first-pass</p><p>elimination. In adults and children beyond one year of age, approximately 90% of the dose is</p><p>metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-</p><p>methylxanthine and hydroxylation to 1 ,3-dimethyluric acid. 1 -methylxanthine is further hydroxylated,</p><p>by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine.</p><p>Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while</p><p>cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid.</p><p>Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a</p><p>closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of</p><p>the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to</p><p>maximal levels by one year of age.</p><p>Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-</p><p>methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum</p><p>concentrations in adults with normal renal function are &lt;1 mcg/mL. In patients with end-stage renal</p><p>disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized</p><p>theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of</p><p>renal function. In neonates, caffeine may accumulate to concentrations that approximate the</p><p>unmetabolized theophylline concentration and thus, exert a pharmacologic effect.</p><p>Both the N-demethylation and hydroxylation pathways of theophylline biotransformation are capacitylimited.</p><p>Due to the wide intersubject variability of the rate of theophylline metabolism, non-linearity of</p><p>elimination may begin in some patients at serum theophylline concentrations &lt;10 mcg/mL. Since this</p><p>non-linearity results in more than proportional changes in serum theophylline concentrations with</p><p>changes in dose, it is advisable to make increases or decreases in dose in small increments in order to</p><p>achieve desired changes in serum theophylline concentrations (see DOSAGE AND</p><p>ADMINISTRATION, Table VI). Accurate prediction of dose-dependency of theophylline metabolism</p><p>in patients <em>a priori </em>is not possible, but patients with very high initial clearance rates (i.e., low steady</p><p>state serum theophylline concentrations at above average doses) have the greatest likelihood of</p><p>experiencing large changes in serum theophylline concentration in response to dosage changes.</p><p><strong>&nbsp;</strong></p><p><strong>Excretion </strong></p><p>In neonates, approximately 50% of the theophylline dose is excreted unchanged in the urine.</p><p>Beyond the first three months of life, approximately 10% of the theophylline dose is excreted</p><p>unchanged in the urine. The remainder is excreted in the urine mainly as 1 ,3-dimethyluric acid (35-</p><p>40%), 1-methyluric acid (20-25%) and 3-methylxanthine (15-20%). Since little theophylline is excreted</p><p>unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do</p><p>not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage</p><p>adjustment for renal insufficiency is necessary in adults and children &gt;3 months of age. In contrast, the</p><p>large fraction of the theophylline dose excreted in the urine as unchanged theophylline and caffeine in</p><p>neonates requires careful attention to dose reduction and frequent monitoring of serum theophylline</p><p>concentrations in neonates with reduced renal function (See WARNINGS).</p><p><strong>&nbsp;</strong></p><p><strong>Serum Concentrations at Steady State </strong></p><p>After multiple doses of theophylline, steady state is reached in</p><p>30-65 hours (average 40 hours) in adults. At steady state, on a dosage regimen with 6-hour intervals,</p><p>the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming</p><p>a mean theophylline half-life of 8 hours. The difference between peak and trough concentrations is</p><p>larger in patients with more rapid theophylline clearance. In patients with high theophylline clearance</p><p>and half-lives of about 4-5 hours, such as children age 1 to 9 years, the trough serum theophylline</p><p>concentration may be only 30% of peak with a 6-hour dosing interval. In these patients a slow release</p><p>formulation would allow a longer dosing interval (8-12 hours) with a smaller peak/trough difference.</p><p>Special Populations</p><p>( <strong>See Table I for mean clearance and half-life values </strong>)</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric </strong></p><p>The clearance of theophylline is decreased by an average of 30% in healthy elderly adults (&gt;</p><p>60 yrs) compared to healthy young adults. Careful attention to dose reduction and frequent monitoring</p><p>of serum theophylline concentrations are required in elderly patients (see WARNINGS).</p><p><strong>Pediatrics </strong>The clearance of theophylline is very low in neonates (see WARNINGS). Theophylline</p><p>clearance reaches maximal values by one year of age, remains relatively constant until about 9 years of</p><p>age and then slowly decreases by approximately 50% to adult values at about age 16. Renal excretion of</p><p>unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in</p><p>children older than three months and in adults. Careful attention to dosage selection and monitoring of</p><p>serum theophylline concentrations are required in pediatric patients (see WARNINGS and DOSAGE</p><p>AND ADMINISTRATION).</p><p><strong>&nbsp;</strong></p><p><strong>Gender </strong></p><p>Gender differences in theophylline clearance are relatively small and unlikely to be of clinical</p><p>significance. Significant reduction in theophylline clearance, however, has been reported in women on</p><p>the 20th day of the menstrual cycle and during the third trimester of pregnancy.</p><p><strong>&nbsp;</strong></p><p><strong>Race </strong></p><p>Pharmacokinetic differences in theophylline clearance due to race have not been studied.</p><p><strong>&nbsp;</strong></p><p><strong>Renal Ins ufficiency </strong></p><p>Only a small fraction, e.g., about 10%, of the administered theophylline dose is</p><p>excreted unchanged in the urine of children greater than three months of age and adults. Since little</p><p>theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e.,</p><p>caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of endstage</p><p>renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children &gt;3</p><p>months of age. In contrast, approximately 50% of the administered theophylline dose is excreted</p><p>unchanged in the urine in neonates. Careful attention to dose reduction and frequent monitoring of serum</p><p>theophylline concentrations are required in neonates with decreased renal function (see WARNINGS).</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic Ins ufficiency </strong></p><p>Theophylline clearance is decreased by 50% or more in patients with hepatic</p><p>insufficiency (e.g., cirrhosis, acute hepatitis, cholestasis). Careful attention to dose reduction and</p><p>frequent monitoring of serum theophylline concentrations are required in patients with reduced hepatic</p><p>function (see WARNINGS).</p><p><strong>&nbsp;</strong></p><p><strong>Conges tive Heart Failure (CHF) </strong></p><p>Theophylline clearance is decreased by 50% or more in patients</p><p>with CHF. The extent of reduction in theophylline clearance in patients with CHF appears to be directly</p><p>correlated to the severity of the cardiac disease. Since theophylline clearance is independent of liver</p><p>blood flow, the reduction in clearance appears to be due to impaired hepatocyte function rather than</p><p>reduced perfusion. Careful attention to dose reduction and frequent monitoring of serum theophylline</p><p>concentrations are required in patients with CHF (see WARNINGS).</p><p><strong>&nbsp;</strong></p><p><strong>Smokers </strong></p><p>Tobacco and marijuana smoking appears to increase the clearance of theophylline by</p><p>induction of metabolic pathways. Theophylline clearance has been shown to increase by approximately</p><p>50% in young adult tobacco smokers and by approximately 80% in elderly tobacco smokers compared</p><p>to non-smoking subjects. Passive smoke exposure has also been shown to increase theophylline</p><p>clearance by up to 50%. Abstinence from tobacco smoking for one week causes a reduction of</p><p>approximately 40% in theophylline clearance. Careful attention to dose reduction and frequent</p><p>monitoring of serum theophylline concentrations are required in patients who stop smoking (see</p><p>WARNINGS). Use of nicotine gum has been shown to have no effect on theophylline clearance.</p><p><strong>&nbsp;</strong></p><p><strong>Fever </strong></p><p>Fever, regardless of its underlying cause, can decrease the clearance of theophylline. The</p><p>magnitude and duration of the fever appear to be directly correlated to the degree of decrease of</p><p>theophylline clearance. Precise data are lacking, but a temperature of 39&deg;C (102&deg;F) for at least 24 hours</p><p>is probably required to produce a clinically significant increase in serum theophylline concentrations.</p><p>Children with rapid rates of theophylline clearance (i.e., those who require a dose that is substantially</p><p>larger than average [e.g., &gt;22 mg/kg/day] to achieve a therapeutic peak serum theophylline concentration</p><p>when afebrile) may be at greater risk of toxic effects from decreased clearance during sustained fever.</p><p>Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are</p><p>required in patients with sustained fever (see WARNINGS).</p><p><strong>&nbsp;</strong></p><p><strong>Miscellaneous</strong></p><p>Other factors associated with decreased theophylline clearance include the third trimester of</p><p>pregnancy, sepsis with multiple organ failure, and hypothyroidism. Careful attention to dose reduction</p><p>and frequent monitoring of serum theophylline concentrations are required in patients with any of these</p><p>conditions (see WARNINGS). Other factors associated with increased theophylline clearance include</p><p>hyperthyroidism and cystic fibrosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with omeprazole. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition. Similar findings have been made after treatment with H<sub>2</sub>-receptor antagonists, proton pump inhibitors and after partial fundectomy. Thus, these changes are not from a direct effect of any individual active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Sorbitol Solution 70% N.C</p><p>Glycerol</p><p>Propylene Glycol</p><p>Sodium Hydroxide</p><p>Sodium Sulphite Anhydrous</p><p>Saccharin Sodium</p><p>Fruit Cocktail Flavor ID-21244</p><p>Peppermint Flavor C-7531</p><p>Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
In-Use : 28 days


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p><p>Store in the original container tightly closed</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber coloured glass bottle with white child resistant plastic cap</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>